Tobey Tayler, Ortega-Loayza Alex G, Choe Sharon I, Haddadin Olivia, Bardazzi Federico, Croitoru David O, Chen Diana M, Vague Morgan, Dini Valentina, Hampton Philip J, Huang William T, Imre Mihaly, Kelly Robert I, Nutan Fnu, Shaigany Sheila, Shakshouk Hadir, Jara Jenny Belén Altamirano, Nolan Barbara, Zeiter Tammi, Kolios Antonios G A, Mostaghimi Arash, Kaffenberger Benjamin H, Prinsen Cecilia A C, Jacobson Michael E
School of Medicine, Oregon Health & Science University, Portland, OR, USA.
Department of Dermatology, Oregon Health & Science University, 3303 S. Bond Avenue, Portland, OR, 97239, USA.
Arch Dermatol Res. 2025 Feb 20;317(1):449. doi: 10.1007/s00403-025-03920-w.
Pyoderma gangrenosum (PG) is a debilitating inflammatory skin condition characterized by painful, necrotic ulcers, significantly impairing patient quality of life. The variability in clinical outcomes and the lack of standardized treatment protocols challenge effective PG clinical management and research. The Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE) project seeks to address this gap by establishing a core outcome set (COS) for PG clinical trials. UPGRADE has reached consensus on three core outcome domains: Pain, Quality of Life, and Clinical Signs. Here we describe a protocol detailing the next steps of UPGRADE's COS development to employ an international multistakeholder modified Delphi consensus process to reach consensus on the content of each core domain through the identification and definition of core domain-specific domain items. The process outlined in this protocol will involve generating domain items from the existing literature, refining these items through iterative e-Delphi surveys, and finalizing them in a consensus meeting. This work will enhance the granularity of these domains and facilitate more precise outcome measurement in clinical trials. The development of these detailed domain items is crucial for standardizing outcome reporting across PG trials, thereby improving research quality and enabling better treatment strategies, ultimately enhancing patient outcomes.
坏疽性脓皮病(PG)是一种使人衰弱的炎症性皮肤病,其特征为疼痛性坏死性溃疡,严重损害患者的生活质量。临床结果的变异性以及缺乏标准化的治疗方案对PG的有效临床管理和研究构成了挑战。“坏疽性脓皮病的理解、疾病影响回顾与评估”(UPGRADE)项目旨在通过为PG临床试验建立核心结局集(COS)来填补这一空白。UPGRADE已就三个核心结局领域达成共识:疼痛、生活质量和临床体征。在此,我们描述了一个方案,详细说明了UPGRADE的COS开发的后续步骤,即采用国际多利益相关方改良德尔菲共识法,通过识别和定义特定于每个核心领域的领域条目,就每个核心领域的内容达成共识。本方案中概述的过程将包括从现有文献中生成领域条目,通过迭代电子德尔菲调查对这些条目进行完善,并在共识会议上确定最终条目。这项工作将提高这些领域的粒度,并有助于在临床试验中进行更精确的结局测量。这些详细领域条目的制定对于规范PG试验中的结局报告至关重要,从而提高研究质量并促成更好的治疗策略,最终改善患者结局。